A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

被引：0
|
作者：
Salles, Gilles [1 ]
Shah, Harsh [2 ]
Leonard, John P. [3 ]
Szanto, Attila [4 ]
Chen, Jade [4 ]
Bannerji, Rajat [4 ]
Morschhauser, Franck [5 ]
Nastoupil, Loretta J. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Weill Cornell Med, New York, NY USA
[4] Epizyme, Cambridge, MA USA
[5] Univ Lille, CHU Lille, ULR 7365, GRITA,Grp Rech Formes Injectables & Technol Assoc, Lille, France
[6] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
IBCL; follicular lymphoma; non-Hodgkin lymphoma; enhancer of zeste homolog 2 protein; epigenetics; tazemetostat; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-485
引用
收藏
页码：S454 / S455
页数：2
相关论文
共 50 条
  • [11] AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2018, 132
  • [12] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [13] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
    Batlevi, Connie Lee
    Salles, Gilles
    Park, Steven, I
    Phillips, Tycel J.
    Amengual, Jennifer E.
    Andorsky, David
    Campbell, Philip
    McKay, Pamela
    Leonard, John P.
    Sondhi, Manu
    Chen, Yingxue
    Slatcher, Pamela L.
    Lin, Richard
    Szanto, Attila
    Abbadi, Sara
    Morschhauser, Franck
    BLOOD, 2022, 140 : 2296 - 2298
  • [14] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
    Andorsky, David Jacob
    Yacoub, Abdulraheem
    Melear, Jason M.
    Coleman, Morton
    Kolibaba, Kathryn S.
    Brooks, Heather Dawn
    Bitran, Jacob D.
    Fanning, Suzanne R.
    Lansigan, Frederick
    Ricker, Justin L.
    Foon, Kenneth A.
    Liu, Dongfang
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [15] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
    Burke, J. M.
    Andorsky, D. J.
    Yacoub, A.
    Melear, J.
    Coleman, M.
    Kolibaba, K.
    Brooks, H.
    Bitran, J.
    Fanning, S.
    Lansigan, F.
    Ricker, J. L.
    Foon, K.
    Llorente, M.
    Li, J.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 249 - 250
  • [16] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
    Sehn, Laurie H.
    Luminari, Stefano
    Scholz, Christian W.
    Huebel, Kai
    Salar, Antonio
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Panayiotidis, Panayiotis
    Lee, Hui-Peng
    Ubieto, Ana Jimenez
    Sancho, Juan-Manuel
    Kim, Tae Min
    Domenech, Eva Domingo
    Kumode, Takahiro
    Poh, Christina
    Thieblemont, Catherine
    Deeren, Dries
    de Wit, Edwin
    Arbushites, Michael
    Casadebaig, Marie-Laure
    Trneny, Marek
    BLOOD, 2024, 144 : LBA1 - LBA4
  • [17] An Externally Controlled Trial to Indirectly Compare Tazemetostat Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab after at Least One Prior Systemic Therapy in Patients with Refractory and Relapsed Follicular Lymphoma
    Nastoupil, Loretta J.
    Salles, Gilles
    Leonard, John P.
    Morschhauser, Frank
    Veazey, Kylee Jordan
    Perrot, Valerie
    Doban, Vitalii
    Bonnet, Marion
    Sosinsky, Alexandra Z.
    Crowley, Aaron
    Lieb, Camryn
    Wang, Zhengfan
    Zeldow, Bret
    Harton, Joanna
    Wang, Shu
    Garawin, Tamer
    BLOOD, 2023, 142
  • [18] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
    Falchi, Lorenzo
    Abrisqueta, Pau
    Nijland, Marcel
    Leppa, Sirpa
    Hutchings, Martin
    Holte, Harald
    Merryman, Reid W.
    Lugtenburg, Pieternella
    de Vos, Sven
    Cheah, Chan Y.
    Christensen, Jacob Haaber
    Arcaini, Luca
    Drott, Kristina
    Hellstrom, Mats
    Leslie, Lori A.
    Vitolo, Umberto
    Rana, Ali
    Abbas, Aqeel
    Wang, Liwei
    Minh Dinh
    Belada, David
    BLOOD, 2022, 140 : 1464 - 1466
  • [19] inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Trneny, Marek
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S402 - S402
  • [20] MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
    Andorsky, David J.
    Yacoub, Abdulraheem
    Bitran, Jacob D.
    Melear, Jason
    Brooks, Heather D.
    Foon, Kenneth A.
    Rizvi, Syed
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff P.
    BLOOD, 2016, 128 (22)
12345